Homology closes $130M AAV manufacturing JV with Oxford; retains 20% stake plus put/call option

Q32 Bio Inc.

Homology transferred AAV manufacturing assets to Newco for 175,000 units, then sold 130,000 units to OXB for $130M cash.
OXB contributed $50M for 50,000 units; post-closing OXB owns 80%, Homology owns 20% of Newco.
After three years, Homology can put (or OXB can call) Homology's Newco stake at 5.5x trailing revenue, subject to cap.
Pro forma shows estimated gain of $145M on derecognition of assets and equity method investment of $45M as of Sept 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.